Skip to main content
. 2021 Jan;10(1):202–220. doi: 10.21037/tlcr-20-674

Figure 4.

Figure 4

Impact of genetic alterations on outcome in terms of overall survival (OS). (A) Impact of TP53 mutation on OS in the study population (treated with immune checkpoint inhibitors); (B) impact of TP53 mutation on OS in the control group (not receiving immune checkpoint inhibitors); (C) impact of KRAS/STK11 co-mutation on OS in the study population (treated with immune checkpoint inhibitors); (D) impact of KRAS/STK11 co-mutation on OS in the control group (not receiving immune checkpoint inhibitors).